Review: HCT for Patients with AML in First Complete Remission

In this review, part of a Blood special review series on acute myeloid leukemia (AML), the authors note that although a majority of patients with AML enter remission upon induction chemotherapy, the risk of relapse is considerable and it varies greatly according to age and genetic subtype. The reviewers further note that although allogeneic hematopoietic cell transplantation (HCT) is the preferred type of post-remission therapy in poor- and very-poor-risk AML, the place of allogeneic HCT in intermediate-risk AML is being debated.

Autologous HCT is considered a valuable alternative that may be preferred in patients without minimal residual disease after induction chemotherapy, the authors write, and they present post-remission transplant strategies using either autologous or allogeneic hematopoietic cells. Additional discussion focuses on recent developments in the field of alternative donors – including cord blood and haploidentical donors – and reduced-intensity allogeneic HCT in older AML recipients.

Cornelissen JJ, et al. Blood

Related Resources